(Total Views: 511)
Posted On: 05/06/2025 10:08:46 AM
Post# of 154593
Yes, CytoDyn's collaboration with Cornell University is active and progressing. In a March 2025 shareholder letter, CEO Dr. Jacob Lalezari confirmed that a pilot study of leronlimab for mild to moderate Alzheimer’s disease is set to take place at Cornell Medical Center in New York. The study is fully funded, and Cornell is currently advancing it through their institutional review process and preparing for FDA submission .
CytoDyn Inc.
While specific financial details regarding payments to Cornell University are not publicly disclosed, the ongoing development and funding of this study indicate that CytoDyn is fulfilling its financial commitments related to this collaboration.
Additionally, CytoDyn's board includes Dr. Lishomwa Ndhlovu, a Professor of Immunology in Medicine and Neuroscience at Weill Cornell Medicine, who has been a director since November 2021 and previously served on the company’s Scientific Advisory Board . His involvement further underscores the active relationship between CytoDyn and Cornell University.
SEC
CytoDyn Inc.
While specific financial details regarding payments to Cornell University are not publicly disclosed, the ongoing development and funding of this study indicate that CytoDyn is fulfilling its financial commitments related to this collaboration.
Additionally, CytoDyn's board includes Dr. Lishomwa Ndhlovu, a Professor of Immunology in Medicine and Neuroscience at Weill Cornell Medicine, who has been a director since November 2021 and previously served on the company’s Scientific Advisory Board . His involvement further underscores the active relationship between CytoDyn and Cornell University.
SEC
(13)
(0)
